JP2020505333A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020505333A5 JP2020505333A5 JP2019537134A JP2019537134A JP2020505333A5 JP 2020505333 A5 JP2020505333 A5 JP 2020505333A5 JP 2019537134 A JP2019537134 A JP 2019537134A JP 2019537134 A JP2019537134 A JP 2019537134A JP 2020505333 A5 JP2020505333 A5 JP 2020505333A5
- Authority
- JP
- Japan
- Prior art keywords
- bis
- diyl
- tetrahydroisoquinoline
- dioxo
- methyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229910052757 nitrogen Inorganic materials 0.000 claims description 158
- -1 Dichloro-2-methyl-1,2,3,4-tetrahydroisoquinoline-4-yl Chemical group 0.000 claims description 103
- 150000001875 compounds Chemical class 0.000 claims description 58
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 claims description 52
- KHBQMWCZKVMBLN-UHFFFAOYSA-N Benzenesulfonamide Chemical compound NS(=O)(=O)C1=CC=CC=C1 KHBQMWCZKVMBLN-UHFFFAOYSA-N 0.000 claims description 32
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 claims description 32
- 125000000623 heterocyclic group Chemical group 0.000 claims description 25
- 125000001072 heteroaryl group Chemical group 0.000 claims description 24
- 125000000217 alkyl group Chemical group 0.000 claims description 23
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 20
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 claims description 20
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 claims description 16
- 239000004202 carbamide Substances 0.000 claims description 16
- 229910052799 carbon Inorganic materials 0.000 claims description 16
- 229910052760 oxygen Inorganic materials 0.000 claims description 16
- 125000003118 aryl group Chemical group 0.000 claims description 14
- 125000000392 cycloalkenyl group Chemical group 0.000 claims description 14
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 14
- 229910052739 hydrogen Inorganic materials 0.000 claims description 14
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 14
- 229910052736 halogen Inorganic materials 0.000 claims description 13
- 150000002367 halogens Chemical class 0.000 claims description 13
- 229910052717 sulfur Inorganic materials 0.000 claims description 12
- 150000003839 salts Chemical class 0.000 claims description 11
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 10
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims description 10
- 125000005842 heteroatom Chemical group 0.000 claims description 10
- 229910052698 phosphorus Inorganic materials 0.000 claims description 10
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 claims description 8
- 239000008194 pharmaceutical composition Substances 0.000 claims description 8
- XTFIVUDBNACUBN-UHFFFAOYSA-N 1,3,5-trinitro-1,3,5-triazinane Chemical compound [O-][N+](=O)N1CN([N+]([O-])=O)CN([N+]([O-])=O)C1 XTFIVUDBNACUBN-UHFFFAOYSA-N 0.000 claims description 6
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims description 6
- 125000001951 carbamoylamino group Chemical group C(N)(=O)N* 0.000 claims description 6
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 6
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 6
- 125000001309 chloro group Chemical group Cl* 0.000 claims description 5
- 239000012453 solvate Substances 0.000 claims description 5
- 208000002551 irritable bowel syndrome Diseases 0.000 claims description 4
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 claims description 3
- 125000004429 atom Chemical group 0.000 claims description 3
- CSTNAQPBOPARIZ-UHFFFAOYSA-N 1-[2-[2-[2-[[3-(6-chloro-2,8-dimethyl-3,4-dihydro-1H-isoquinolin-4-yl)-4-methylphenyl]sulfonylamino]ethoxy]ethoxy]ethyl]-3-[4-[2-[2-[2-[[3-(6-chloro-2,8-dimethyl-3,4-dihydro-1H-isoquinolin-4-yl)-4-methylphenyl]sulfonylamino]ethoxy]ethoxy]ethylcarbamoylamino]butyl]urea Chemical compound O=C(NCCOCCOCCNS(=O)(=O)C1=CC(=C(C=C1)C)C1CN(CC2=C(C=C(C=C12)Cl)C)C)NCCCCNC(NCCOCCOCCNS(=O)(=O)C1=CC(=C(C=C1)C)C1CN(CC2=C(C=C(C=C12)Cl)C)C)=O CSTNAQPBOPARIZ-UHFFFAOYSA-N 0.000 claims description 2
- LPOOAIYWJXCQLO-UHFFFAOYSA-N 1-[2-[2-[2-[[3-(6-chloro-2,8-dimethyl-3,4-dihydro-1H-isoquinolin-4-yl)phenyl]sulfonylamino]ethoxy]ethoxy]ethyl]-3-[4-[2-[2-[2-[[3-(6-chloro-2,8-dimethyl-3,4-dihydro-1H-isoquinolin-4-yl)phenyl]sulfonylamino]ethoxy]ethoxy]ethylcarbamoylamino]butyl]urea Chemical compound O=C(NCCOCCOCCNS(=O)(=O)C1=CC(=CC=C1)C1CN(CC2=C(C=C(C=C12)Cl)C)C)NCCCCNC(NCCOCCOCCNS(=O)(=O)C1=CC(=CC=C1)C1CN(CC2=C(C=C(C=C12)Cl)C)C)=O LPOOAIYWJXCQLO-UHFFFAOYSA-N 0.000 claims description 2
- JQJNCRYEIZDJMD-UHFFFAOYSA-N 1-[2-[2-[2-[[3-(6-chloro-8-cyano-2-methyl-3,4-dihydro-1H-isoquinolin-4-yl)-4-fluorophenyl]sulfonylamino]ethoxy]ethoxy]ethyl]-3-[4-[2-[2-[2-[[3-(6-chloro-8-cyano-2-methyl-3,4-dihydro-1H-isoquinolin-4-yl)-4-fluorophenyl]sulfonylamino]ethoxy]ethoxy]ethylcarbamoylamino]butyl]urea Chemical compound O=C(NCCOCCOCCNS(=O)(=O)C1=CC(=C(C=C1)F)C1CN(CC2=C(C=C(C=C12)Cl)C#N)C)NCCCCNC(NCCOCCOCCNS(=O)(=O)C1=CC(=C(C=C1)F)C1CN(CC2=C(C=C(C=C12)Cl)C#N)C)=O JQJNCRYEIZDJMD-UHFFFAOYSA-N 0.000 claims description 2
- FVAPOYPJYNUIPS-UHFFFAOYSA-N 1-[2-[2-[2-[[3-(6-chloro-8-cyano-2-methyl-3,4-dihydro-1H-isoquinolin-4-yl)-4-methylphenyl]sulfonylamino]ethoxy]ethoxy]ethyl]-3-[4-[2-[2-[2-[[3-(6-chloro-8-cyano-2-methyl-3,4-dihydro-1H-isoquinolin-4-yl)-4-methylphenyl]sulfonylamino]ethoxy]ethoxy]ethylcarbamoylamino]butyl]urea Chemical compound CN1CC(C2=C(C)C=CC(=C2)S(=O)(=O)NCCOCCOCCNC(=O)NCCCCNC(=O)NCCOCCOCCNS(=O)(=O)C2=CC(C3CN(C)CC4=C3C=C(Cl)C=C4C#N)=C(C)C=C2)C2=C(C1)C(=CC(Cl)=C2)C#N FVAPOYPJYNUIPS-UHFFFAOYSA-N 0.000 claims description 2
- RYXAQGKLQHUUBT-UHFFFAOYSA-N 1-[2-[2-[2-[[3-(6-chloro-8-cyano-2-methyl-3,4-dihydro-1H-isoquinolin-4-yl)phenyl]sulfonylamino]ethoxy]ethoxy]ethyl]-3-[4-[2-[2-[2-[[3-(6-chloro-8-cyano-2-methyl-3,4-dihydro-1H-isoquinolin-4-yl)phenyl]sulfonylamino]ethoxy]ethoxy]ethylcarbamoylamino]butyl]urea Chemical compound O=C(NCCOCCOCCNS(=O)(=O)C1=CC(=CC=C1)C1CN(CC2=C(C=C(C=C12)Cl)C#N)C)NCCCCNC(NCCOCCOCCNS(=O)(=O)C1=CC(=CC=C1)C1CN(CC2=C(C=C(C=C12)Cl)C#N)C)=O RYXAQGKLQHUUBT-UHFFFAOYSA-N 0.000 claims description 2
- INJBESAYBAGURN-UHFFFAOYSA-N 1-[2-[2-[2-[[5-(6,8-dichloro-2-methyl-3,4-dihydro-1H-isoquinolin-4-yl)-2-methylphenyl]sulfonylamino]ethoxy]ethoxy]ethyl]-3-[4-[2-[2-[2-[[5-(6,8-dichloro-2-methyl-3,4-dihydro-1H-isoquinolin-4-yl)-2-methylphenyl]sulfonylamino]ethoxy]ethoxy]ethylcarbamoylamino]butyl]urea Chemical compound CN1CC(C2=CC(=C(C)C=C2)S(=O)(=O)NCCOCCOCCNC(=O)NCCCCNC(=O)NCCOCCOCCNS(=O)(=O)C2=C(C)C=CC(=C2)C2CN(C)CC3=C2C=C(Cl)C=C3Cl)C2=C(C1)C(Cl)=CC(Cl)=C2 INJBESAYBAGURN-UHFFFAOYSA-N 0.000 claims description 2
- BUZIFTBLDVYRMI-UHFFFAOYSA-N 1-[2-[2-[2-[[5-(6-chloro-2,8-dimethyl-3,4-dihydro-1H-isoquinolin-4-yl)-2-methylphenyl]sulfonylamino]ethoxy]ethoxy]ethyl]-3-[4-[2-[2-[2-[[5-(6-chloro-2,8-dimethyl-3,4-dihydro-1H-isoquinolin-4-yl)-2-methylphenyl]sulfonylamino]ethoxy]ethoxy]ethylcarbamoylamino]butyl]urea Chemical compound O=C(NCCOCCOCCNS(=O)(=O)C1=C(C=CC(=C1)C1CN(CC2=C(C=C(C=C12)Cl)C)C)C)NCCCCNC(NCCOCCOCCNS(=O)(=O)C1=C(C=CC(=C1)C1CN(CC2=C(C=C(C=C12)Cl)C)C)C)=O BUZIFTBLDVYRMI-UHFFFAOYSA-N 0.000 claims description 2
- DPBWFNDFMCCGGJ-UHFFFAOYSA-N 4-Piperidine carboxamide Chemical compound NC(=O)C1CCNCC1 DPBWFNDFMCCGGJ-UHFFFAOYSA-N 0.000 claims description 2
- MGZVSYCVURJMKP-ACEFPKFPSA-N CN1C[C@H](C2=C(C1)C(=CC(=C2)Cl)Cl)C3=CC(=CC=C3)S(=O)(=O)N4CCC(CC4)C(CCNC(=O)NCCCCNC(=O)NCCCC(=O)N)C(=O)N Chemical compound CN1C[C@H](C2=C(C1)C(=CC(=C2)Cl)Cl)C3=CC(=CC=C3)S(=O)(=O)N4CCC(CC4)C(CCNC(=O)NCCCCNC(=O)NCCCC(=O)N)C(=O)N MGZVSYCVURJMKP-ACEFPKFPSA-N 0.000 claims description 2
- 125000001153 fluoro group Chemical group F* 0.000 claims description 2
- BVOCPVIXARZNQN-UHFFFAOYSA-N nipecotamide Chemical compound NC(=O)C1CCCNC1 BVOCPVIXARZNQN-UHFFFAOYSA-N 0.000 claims description 2
- 229940124530 sulfonamide Drugs 0.000 claims description 2
- 150000003456 sulfonamides Chemical class 0.000 claims description 2
- 201000005991 hyperphosphatemia Diseases 0.000 claims 1
- 239000002904 solvent Substances 0.000 claims 1
- 206010010774 Constipation Diseases 0.000 description 29
- 238000000034 method Methods 0.000 description 16
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 12
- 208000011580 syndromic disease Diseases 0.000 description 11
- 230000001684 chronic effect Effects 0.000 description 10
- 208000035475 disorder Diseases 0.000 description 8
- 208000020832 chronic kidney disease Diseases 0.000 description 7
- 201000003883 Cystic fibrosis Diseases 0.000 description 6
- 208000007530 Essential hypertension Diseases 0.000 description 6
- 208000018522 Gastrointestinal disease Diseases 0.000 description 6
- 206010019280 Heart failures Diseases 0.000 description 6
- 206010020772 Hypertension Diseases 0.000 description 6
- 208000024780 Urticaria Diseases 0.000 description 6
- 210000001072 colon Anatomy 0.000 description 6
- 208000030159 metabolic disease Diseases 0.000 description 6
- 208000015943 Coeliac disease Diseases 0.000 description 5
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 5
- 208000008589 Obesity Diseases 0.000 description 4
- 108091006649 SLC9A3 Proteins 0.000 description 4
- 102100030375 Sodium/hydrogen exchanger 3 Human genes 0.000 description 4
- 208000038016 acute inflammation Diseases 0.000 description 4
- 230000006022 acute inflammation Effects 0.000 description 4
- 230000001476 alcoholic effect Effects 0.000 description 4
- 125000003545 alkoxy group Chemical group 0.000 description 4
- 125000000304 alkynyl group Chemical group 0.000 description 4
- 208000037976 chronic inflammation Diseases 0.000 description 4
- 230000006020 chronic inflammation Effects 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000016097 disease of metabolism Diseases 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 210000001035 gastrointestinal tract Anatomy 0.000 description 4
- 125000001188 haloalkyl group Chemical group 0.000 description 4
- 208000006454 hepatitis Diseases 0.000 description 4
- 231100000283 hepatitis Toxicity 0.000 description 4
- 239000003112 inhibitor Substances 0.000 description 4
- 208000019423 liver disease Diseases 0.000 description 4
- 235000020824 obesity Nutrition 0.000 description 4
- 206010001605 Alcohol poisoning Diseases 0.000 description 3
- 201000004384 Alopecia Diseases 0.000 description 3
- 206010003645 Atopy Diseases 0.000 description 3
- 208000008439 Biliary Liver Cirrhosis Diseases 0.000 description 3
- 206010007559 Cardiac failure congestive Diseases 0.000 description 3
- 206010008609 Cholangitis sclerosing Diseases 0.000 description 3
- 206010008874 Chronic Fatigue Syndrome Diseases 0.000 description 3
- 206010009900 Colitis ulcerative Diseases 0.000 description 3
- 208000011231 Crohn disease Diseases 0.000 description 3
- 208000007342 Diabetic Nephropathies Diseases 0.000 description 3
- 206010012742 Diarrhoea infectious Diseases 0.000 description 3
- 208000004232 Enteritis Diseases 0.000 description 3
- 208000001640 Fibromyalgia Diseases 0.000 description 3
- 206010016654 Fibrosis Diseases 0.000 description 3
- 208000004262 Food Hypersensitivity Diseases 0.000 description 3
- 206010016946 Food allergy Diseases 0.000 description 3
- 208000017228 Gastrointestinal motility disease Diseases 0.000 description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 3
- 208000030053 Opioid-Induced Constipation Diseases 0.000 description 3
- 208000012868 Overgrowth Diseases 0.000 description 3
- 208000018737 Parkinson disease Diseases 0.000 description 3
- 208000012654 Primary biliary cholangitis Diseases 0.000 description 3
- 208000025747 Rheumatic disease Diseases 0.000 description 3
- 102100022897 Sodium/hydrogen exchanger 10 Human genes 0.000 description 3
- 201000002661 Spondylitis Diseases 0.000 description 3
- 208000007107 Stomach Ulcer Diseases 0.000 description 3
- 208000025865 Ulcer Diseases 0.000 description 3
- 201000006704 Ulcerative Colitis Diseases 0.000 description 3
- 206010047115 Vasculitis Diseases 0.000 description 3
- 231100000360 alopecia Toxicity 0.000 description 3
- 230000002337 anti-port Effects 0.000 description 3
- 208000029560 autism spectrum disease Diseases 0.000 description 3
- 230000001580 bacterial effect Effects 0.000 description 3
- 208000014797 chronic intestinal pseudoobstruction Diseases 0.000 description 3
- 230000007882 cirrhosis Effects 0.000 description 3
- 208000019425 cirrhosis of liver Diseases 0.000 description 3
- 208000010643 digestive system disease Diseases 0.000 description 3
- 208000001848 dysentery Diseases 0.000 description 3
- 235000020932 food allergy Nutrition 0.000 description 3
- 201000005917 gastric ulcer Diseases 0.000 description 3
- 208000018685 gastrointestinal system disease Diseases 0.000 description 3
- 208000007386 hepatic encephalopathy Diseases 0.000 description 3
- 239000001257 hydrogen Substances 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 208000017169 kidney disease Diseases 0.000 description 3
- 230000001404 mediated effect Effects 0.000 description 3
- 201000006417 multiple sclerosis Diseases 0.000 description 3
- 208000029766 myalgic encephalomeyelitis/chronic fatigue syndrome Diseases 0.000 description 3
- 230000002956 necrotizing effect Effects 0.000 description 3
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 description 3
- 208000007232 portal hypertension Diseases 0.000 description 3
- 201000000742 primary sclerosing cholangitis Diseases 0.000 description 3
- 230000000552 rheumatic effect Effects 0.000 description 3
- 206010039073 rheumatoid arthritis Diseases 0.000 description 3
- 201000000980 schizophrenia Diseases 0.000 description 3
- 208000010157 sclerosing cholangitis Diseases 0.000 description 3
- 229910052708 sodium Inorganic materials 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 230000007863 steatosis Effects 0.000 description 3
- 231100000240 steatosis hepatitis Toxicity 0.000 description 3
- 206010043778 thyroiditis Diseases 0.000 description 3
- 230000001256 tonic effect Effects 0.000 description 3
- 208000024172 Cardiovascular disease Diseases 0.000 description 2
- 208000017701 Endocrine disease Diseases 0.000 description 2
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 2
- 208000034486 Multi-organ failure Diseases 0.000 description 2
- 206010068620 Post procedural constipation Diseases 0.000 description 2
- 206010054048 Postoperative ileus Diseases 0.000 description 2
- 206010039509 Scab Diseases 0.000 description 2
- 208000034189 Sclerosis Diseases 0.000 description 2
- 208000005770 Secondary Hyperparathyroidism Diseases 0.000 description 2
- 206010040047 Sepsis Diseases 0.000 description 2
- 229940035676 analgesics Drugs 0.000 description 2
- 239000000730 antalgic agent Substances 0.000 description 2
- 230000002921 anti-spasmodic effect Effects 0.000 description 2
- 239000001961 anticonvulsive agent Substances 0.000 description 2
- 239000000935 antidepressant agent Substances 0.000 description 2
- 229940005513 antidepressants Drugs 0.000 description 2
- 206010003246 arthritis Diseases 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 229940069978 calcium supplement Drugs 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 230000003111 delayed effect Effects 0.000 description 2
- 230000001079 digestive effect Effects 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 125000004438 haloalkoxy group Chemical group 0.000 description 2
- 208000019622 heart disease Diseases 0.000 description 2
- 150000004677 hydrates Chemical class 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- 208000008275 microscopic colitis Diseases 0.000 description 2
- 208000029744 multiple organ dysfunction syndrome Diseases 0.000 description 2
- 230000002981 neuropathic effect Effects 0.000 description 2
- 201000001119 neuropathy Diseases 0.000 description 2
- 230000007823 neuropathy Effects 0.000 description 2
- 208000033808 peripheral neuropathy Diseases 0.000 description 2
- 229940002612 prodrug Drugs 0.000 description 2
- 239000000651 prodrug Substances 0.000 description 2
- 210000000813 small intestine Anatomy 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 2
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 206010016807 Fluid retention Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 208000010718 Multiple Organ Failure Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 206010033799 Paralysis Diseases 0.000 description 1
- 102000003728 Peroxisome Proliferator-Activated Receptors Human genes 0.000 description 1
- 108090000029 Peroxisome Proliferator-Activated Receptors Proteins 0.000 description 1
- 206010051379 Systemic Inflammatory Response Syndrome Diseases 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000001773 anti-convulsant effect Effects 0.000 description 1
- 230000001430 anti-depressive effect Effects 0.000 description 1
- 230000003276 anti-hypertensive effect Effects 0.000 description 1
- 229940125681 anticonvulsant agent Drugs 0.000 description 1
- 229960003965 antiepileptics Drugs 0.000 description 1
- 239000002220 antihypertensive agent Substances 0.000 description 1
- 229940127088 antihypertensive drug Drugs 0.000 description 1
- 239000000164 antipsychotic agent Substances 0.000 description 1
- 229940005529 antipsychotics Drugs 0.000 description 1
- 229940124575 antispasmodic agent Drugs 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000000812 cholinergic antagonist Substances 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 208000028208 end stage renal disease Diseases 0.000 description 1
- 201000000523 end stage renal failure Diseases 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 208000021302 gastroesophageal reflux disease Diseases 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000007154 intracellular accumulation Effects 0.000 description 1
- 208000002741 leukoplakia Diseases 0.000 description 1
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 description 1
- 229940005483 opioid analgesics Drugs 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 210000001578 tight junction Anatomy 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762444338P | 2017-01-09 | 2017-01-09 | |
| US62/444,338 | 2017-01-09 | ||
| PCT/US2018/013027 WO2018129557A1 (en) | 2017-01-09 | 2018-01-09 | Inhibitors of nhe-mediated antiport |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020505333A JP2020505333A (ja) | 2020-02-20 |
| JP2020505333A5 true JP2020505333A5 (enExample) | 2021-02-25 |
Family
ID=61074570
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019537134A Pending JP2020505333A (ja) | 2017-01-09 | 2018-01-09 | Ｎｈｅ媒介性アンチポートの阻害薬 |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US11147884B2 (enExample) |
| EP (1) | EP3565811A1 (enExample) |
| JP (1) | JP2020505333A (enExample) |
| KR (1) | KR20190128626A (enExample) |
| CN (1) | CN110291082A (enExample) |
| AU (1) | AU2018206479B2 (enExample) |
| BR (1) | BR112019013963A2 (enExample) |
| CA (1) | CA3049679A1 (enExample) |
| EA (1) | EA201991676A1 (enExample) |
| IL (1) | IL267821B2 (enExample) |
| MA (1) | MA47203A (enExample) |
| MX (1) | MX2019008171A (enExample) |
| WO (1) | WO2018129557A1 (enExample) |
| ZA (1) | ZA201904460B (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2020181555A1 (zh) * | 2019-03-14 | 2020-09-17 | 深圳仁泰医药科技有限公司 | Nhe3抑制剂的晶型a及其制备方法和应用 |
| CN112679427B (zh) * | 2019-10-17 | 2023-05-12 | 江苏恒瑞医药股份有限公司 | 四氢异喹啉类衍生物、其制备方法及其在医药上的应用 |
| IL303799A (en) * | 2020-12-18 | 2023-08-01 | Shanghai Jemincare Pharmaceuticals Co Ltd | TETRAHYDROISOQUINOLINE COMPOUND IN SUBSTITUTE BENZOHETROCYCLE |
| CN114716458A (zh) * | 2021-01-04 | 2022-07-08 | 上海济煜医药科技有限公司 | 四氢异喹啉类化合物 |
| CN114805202A (zh) * | 2021-01-28 | 2022-07-29 | 江西济民可信集团有限公司 | 苯磺酰胺类化合物及其制备方法和应用 |
| CN113636960A (zh) * | 2021-08-24 | 2021-11-12 | 上海皓元医药股份有限公司 | 一种2-(氯磺酰基)环己烷-1-烯甲酸乙酯衍生物的制备方法 |
| CN117462525B (zh) * | 2023-09-06 | 2024-11-15 | 广州市第一人民医院（广州消化疾病中心、广州医科大学附属市一人民医院、华南理工大学附属第二医院） | 衣康酸在治疗坏死性小肠结肠炎患者中的应用 |
Family Cites Families (128)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3926891A (en) | 1974-03-13 | 1975-12-16 | Dow Chemical Co | Method for making a crosslinkable aqueous solution which is useful to form soft, water-swellable polyacrylate articles |
| US3935099A (en) | 1974-04-03 | 1976-01-27 | The United States Of America As Represented By The Secretary Of Agriculture | Method of reducing water content of emulsions, suspensions, and dispersions with highly absorbent starch-containing polymeric compositions |
| US3997484A (en) | 1974-04-03 | 1976-12-14 | The United States Of America As Represented By The Secretary Of Agriculture | Highly-absorbent starch-containing polymeric compositions |
| US4090013A (en) | 1975-03-07 | 1978-05-16 | National Starch And Chemical Corp. | Absorbent composition of matter |
| JPS51125468A (en) | 1975-03-27 | 1976-11-01 | Sanyo Chem Ind Ltd | Method of preparing resins of high water absorbency |
| JPS5346389A (en) | 1976-10-07 | 1978-04-25 | Kao Corp | Preparation of self-crosslinking polymer of acrylic alkali metal salt |
| US4190562A (en) | 1977-04-04 | 1980-02-26 | The B. F. Goodrich Company | Improved water absorbent copolymers of copolymerizable carboxylic acids and acrylic or methacrylic esters |
| US4470975A (en) | 1977-10-21 | 1984-09-11 | The Johns Hopkins University | Method and composition for the elimination of water from an animal body |
| US4286082A (en) | 1979-04-06 | 1981-08-25 | Nippon Shokubai Kagaku Kogyo & Co., Ltd. | Absorbent resin composition and process for producing same |
| JPS6025045B2 (ja) | 1980-03-19 | 1985-06-15 | 製鉄化学工業株式会社 | 塩水吸収能のすぐれたアクリル酸重合体の製造方法 |
| JPS57158209A (en) | 1981-03-25 | 1982-09-30 | Kao Corp | Production of bead-form highly water-absorbing polymer |
| JPS5832607A (ja) | 1981-08-20 | 1983-02-25 | Kao Corp | 吸水性に優れた吸水材料の製造法 |
| US4985518A (en) | 1981-10-26 | 1991-01-15 | American Colloid Company | Process for preparing water-absorbing resins |
| JPS6187702A (ja) | 1984-10-05 | 1986-05-06 | Seitetsu Kagaku Co Ltd | 吸水性樹脂の製造方法 |
| US4708997A (en) | 1985-07-22 | 1987-11-24 | The Dow Chemical Company | Suspending agent for the suspension polymerization of water-soluble monomers |
| US4806532A (en) | 1985-10-08 | 1989-02-21 | Mayo Foundation For Medical Education And Research | Inhibition of epithelial phosphate transport |
| DE3544770A1 (de) | 1985-12-18 | 1987-06-19 | Stockhausen Chem Fab Gmbh | Verfahren und vorrichtung zum kontinuierlichen herstellen von polymerisaten und copolymerisaten der acrylsaeure und/oder methacrylsaeure |
| US4766004A (en) | 1986-12-19 | 1988-08-23 | Warner-Lambert Company | Crunchy, highly palatable, bulk-increasing, dietary fiber supplement composition |
| IT1217123B (it) | 1987-02-05 | 1990-03-14 | Rotta Research Lab | Derivati otticamente attivi dell acido 5 pentilammino 5 oxo pentanoico r ad attivita antagonista della colecistochinina e procedimento per la loro preparazione |
| US4999200A (en) | 1987-12-09 | 1991-03-12 | Marion Laboratories | Psyllium tablet composition, method of manufacture and method of use |
| US5149541A (en) | 1988-10-03 | 1992-09-22 | The Procter & Gamble Company | Psyllium-containing produces with a distribution of particle size |
| US5145906A (en) | 1989-09-28 | 1992-09-08 | Hoechst Celanese Corporation | Super-absorbent polymer having improved absorbency properties |
| US5126150A (en) | 1990-10-01 | 1992-06-30 | The Procter & Gamble Company | Compositions containing psyllium |
| HUT64023A (en) | 1991-03-22 | 1993-11-29 | Sandoz Ag | Process for producing aminoguanidine derivatives and pharmaceutical compositions comprising such compounds |
| FR2674849B1 (fr) | 1991-04-02 | 1994-12-23 | Logeais Labor Jacques | Nouveaux derives de n-cyclohexyl benzamides ou thiobenzamides, leurs preparations et leurs applications en therapeutique. |
| US5140102A (en) | 1991-09-23 | 1992-08-18 | Monsanto Company | Pentadecapeptide, guanylin, which stimulates intestinal guanylate cyclase |
| US5824645A (en) | 1991-12-30 | 1998-10-20 | Neurex Corporation | Method of treating inflammation |
| CA2151741C (en) | 1991-12-30 | 2001-12-11 | Alan Justice | Methods of producing analgesia and enhancing opiate analgesia |
| US5969097A (en) | 1992-06-23 | 1999-10-19 | G. D. Searle & Co. | Human guanylin |
| EP0612723B1 (de) | 1993-02-20 | 1997-08-27 | Hoechst Aktiengesellschaft | Substituierte Benzoylguanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament, als Inhibitoren des zellulären Na+/H+-Austauschs oder als Diagnostikum sowie sie enthaltendes Medikament |
| US5629377A (en) | 1993-03-10 | 1997-05-13 | The Dow Chemical Company | Water absorbent resin particles of crosslinked carboxyl containing polymers and method of preparation |
| IL109570A0 (en) | 1993-05-17 | 1994-08-26 | Fujisawa Pharmaceutical Co | Guanidine derivatives, pharmaceutical compositions containing the same and processes for the preparation thereof |
| US5489670A (en) | 1993-10-29 | 1996-02-06 | G. D. Searle & Co. | Human uroguanylin |
| US5610145A (en) | 1994-04-15 | 1997-03-11 | Warner-Lambert Company | Tachykinin antagonists |
| US5650222A (en) | 1995-01-10 | 1997-07-22 | The Procter & Gamble Company | Absorbent foam materials for aqueous fluids made from high internal phase emulsions having very high water-to-oil ratios |
| DE19518796A1 (de) | 1995-05-22 | 1996-11-28 | Hoechst Ag | Fluorphenylsubstituierte Alkenylcarbonsäure-guanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament |
| ATE359086T1 (de) | 1995-06-27 | 2007-05-15 | Eisai R&D Man Co Ltd | Zusammensetzungen zur erzielung von analgesie und zur hemmung der progression neuropathischer schmerzerkrankungen |
| US6054429A (en) | 1996-03-08 | 2000-04-25 | Elan Pharmaceuticals, Inc. | Epidural method of producing analgesia |
| US5795864A (en) | 1995-06-27 | 1998-08-18 | Neurex Corporation | Stable omega conopetide formulations |
| US5550167A (en) | 1995-08-30 | 1996-08-27 | The Procter & Gamble Company | Absorbent foams made from high internal phase emulsions useful for acquiring aqueous fluids |
| GB9524104D0 (en) | 1995-11-24 | 1996-01-24 | Smithkline Beecham Spa | Novel compounds |
| EA002124B1 (ru) | 1995-11-24 | 2001-12-24 | Смитклайн Бичам С.П.А. | Производные хинолина |
| DE19548812A1 (de) | 1995-12-27 | 1997-07-03 | Hoechst Ag | Verwendung von Inhibitoren des zellulären Na·+·/H·+·-Exchangers (NHE) zur Herstellung eines Medikaments zur Atemstimulation |
| EP0837055A1 (en) | 1996-07-30 | 1998-04-22 | Hoechst Aktiengesellschaft | Substituted Indanylidineacetylguanidines, process for their preparation, their use as medicaments or diagnostic and medicaments containing them |
| DE19633966A1 (de) | 1996-08-22 | 1998-02-26 | Hoechst Ag | Phenylsubstituierte Alkenylcarbonsäure-guanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament |
| WO1998011090A2 (en) | 1996-09-16 | 1998-03-19 | Warner-Lambert Company | 3-alkyl-3-phenyl-piperidines |
| JP2001513097A (ja) | 1997-02-28 | 2001-08-28 | ビイク グルデン ロンベルク ヒエーミツシエ フアブリーク ゲゼルシヤフト ミツト ベシユレンクテル ハフツング | Ｐｄｅ−抑制物質とアデニル酸シクラーゼ・アゴニストもしくはグアニル酸シクラーゼ・アゴニストとからなる相乗的組み合わせ組成物 |
| NZ329807A (en) | 1997-04-23 | 2000-07-28 | Pfizer | NK-1 receptor antagonists and P receptor antagonists 2-Diarylmethyl-3-amino-1-azabicyclo[2.2.2]octane derivatives and amino substituted N-containing rings as agents for treating irritable bowel syndrome |
| KR100219918B1 (ko) | 1997-07-03 | 1999-09-01 | 김윤 | 대장선택적 약물전달용 조성물 |
| US20010006972A1 (en) | 1998-04-21 | 2001-07-05 | Stephen A. Williams | Nk-1 receptor antagonists for the treatment of symptoms of irritable bowel syndrome |
| KR20000011247A (ko) | 1998-07-23 | 2000-02-25 | 김윤 | 다당류를이용한대장선택성약물전달조성물및약학제제 |
| DE19849722A1 (de) | 1998-10-28 | 2000-05-04 | Aventis Pharma Gmbh | Substituierte Phenyl-alkenoylguanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament |
| AU3213200A (en) | 1999-01-21 | 2000-08-07 | Board Of Regents, The University Of Texas System | Inhibitors of intestinal apical membrane na/phosphate co-transportation |
| FR2789493B1 (fr) | 1999-02-09 | 2001-03-09 | Gemplus Card Int | Procede de detection d'objets portables et systeme de mise en oeuvre |
| US6624150B2 (en) | 1999-02-26 | 2003-09-23 | Inspire Pharmaceuticals, Inc. | Method of treating gastrointestinal tract disease with purinergic receptor agonists |
| US6287609B1 (en) | 1999-06-09 | 2001-09-11 | Wisconsin Alumni Research Foundation | Unfermented gel fraction from psyllium seed husks |
| JP2004513870A (ja) | 1999-07-19 | 2004-05-13 | ザ・ユニヴァーシティ・オヴ・ノース・キャロライナ・アト・チャペル・ヒル | ナトリウムチャネルブロッカーの結合物及びその使用法 |
| CO5190714A1 (es) | 1999-07-20 | 2002-08-29 | Smithkline Beecham Corp | Inhibidores del transporte de fosfato |
| US6107356A (en) | 1999-08-23 | 2000-08-22 | The Procter & Gamble Company | High suction polymeric foam materials |
| DE19941764A1 (de) | 1999-09-02 | 2001-03-15 | Aventis Pharma Gmbh | Substituierte Acylguanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikamente oder Diagnostika sowie sie enthaltende Medikamente |
| SE9903291D0 (sv) | 1999-09-15 | 1999-09-15 | Astra Ab | New process |
| DE19945302A1 (de) | 1999-09-22 | 2001-03-29 | Merck Patent Gmbh | Biphenylderivate als NHE-3-Inhibitoren |
| DE60021521T4 (de) * | 1999-09-29 | 2006-09-21 | Ortho-Mcneil Pharmaceutical, Inc. | Isonipecotamide zur behandlung von integrin vermittelten störungen |
| US6887870B1 (en) | 1999-10-12 | 2005-05-03 | Bristol-Myers Squibb Company | Heterocyclic sodium/proton exchange inhibitors and method |
| EP1225897B1 (en) | 1999-11-01 | 2004-09-08 | RHODES, John | Composition for treatment of constipation and irritable bowel syndrome |
| AUPQ514600A0 (en) | 2000-01-18 | 2000-02-10 | James Cook University | Brain injury treatment |
| WO2001064212A1 (en) | 2000-03-01 | 2001-09-07 | University College London | Modulators of the endocannabinoid uptake and of the vallinoid receptors |
| DE10015248A1 (de) | 2000-03-28 | 2001-10-04 | Merck Patent Gmbh | Bisamidino-Verbindungen als NHE-3 Inhibitoren |
| DE10019062A1 (de) | 2000-04-18 | 2001-10-25 | Merck Patent Gmbh | 2-Guanidino-4-aryl-chinazoline als NHE-3 Inhibitoren |
| JP2003531856A (ja) | 2000-05-02 | 2003-10-28 | スミスクライン・ビーチャム・コーポレイション | リン酸輸送阻害剤 |
| AU2001261471A1 (en) | 2000-05-12 | 2001-11-26 | Smithkline Beecham Corporation | Phosphate transport inhibitors |
| DE10043667A1 (de) | 2000-09-05 | 2002-03-14 | Merck Patent Gmbh | 2-Guanidino-4-aryl-chinazoline |
| US6414016B1 (en) | 2000-09-05 | 2002-07-02 | Sucampo, A.G. | Anti-constipation composition |
| DE10046993A1 (de) | 2000-09-22 | 2002-04-11 | Aventis Pharma Gmbh | Substituierte Zimtsäureguanidide, Verfahren zur ihrer Herstellung, ihre Verwendung als Medikament sowie sie enthaltendes Medikament |
| AU2002213048A1 (en) | 2000-10-05 | 2002-04-15 | Smith Kline Beecham Corporation | Phosphate transport inhibitors |
| US6908609B2 (en) | 2000-11-20 | 2005-06-21 | Dow Global Technologies Inc. | In vivo use of water absorbent polymers |
| DE10063294A1 (de) | 2000-12-19 | 2002-07-04 | Aventis Pharma Gmbh | Substituierte Heterocyclo-Norbornylamino-Derivate, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament |
| CA2905585C (en) | 2001-03-29 | 2020-02-18 | Synergy Pharmaceuticals, Inc. | Guanylate cyclase receptor agonists for the treatment and/or prevention of cancer or polyps |
| US6736705B2 (en) | 2001-04-27 | 2004-05-18 | Hitachi Global Storage Technologies | Polishing process for glass or ceramic disks used in disk drive data storage devices |
| US20030216449A1 (en) | 2001-05-11 | 2003-11-20 | Joseph Weinstock | Phosphate transport inhibitors |
| MY134211A (en) | 2001-05-18 | 2007-11-30 | Smithkline Beecham Corp | Novel use |
| JP2007131532A (ja) | 2001-09-28 | 2007-05-31 | Kirin Brewery Co Ltd | 生体内リン輸送を阻害する化合物およびそれを含んでなる医薬 |
| FR2830451B1 (fr) | 2001-10-09 | 2004-04-30 | Inst Nat Sante Rech Med | Utilisation de peptides analogues de la thymuline(pat)pour la fabrication de medicaments contre la douleur |
| US6911453B2 (en) | 2001-12-05 | 2005-06-28 | Aventis Pharma Deutschland Gmbh | Substituted 4-phenyltetrahydroisoquinolinium, process for their preparation, their use as a medicament, and medicament containing them |
| NZ533322A (en) | 2001-12-05 | 2006-02-24 | Sanofi Aventis Deutschland | Substituted 4-phenyltetrahydroisoquinolines, method for the production thereof, the use thereof as medicaments, in addition to a medicament containing same |
| WO2003048134A1 (en) | 2001-12-05 | 2003-06-12 | Japan Tobacco Inc. | Triazole compound and medicinal use thereof |
| DE10161767A1 (de) | 2001-12-15 | 2003-06-26 | Merck Patent Gmbh | 2-Guanidino-4-heterocyclyl-chinazoline |
| EP1321142A1 (en) | 2001-12-21 | 2003-06-25 | Novartis AG | Solid pharmaceutical composition for oral administration of Tegaserod |
| US6703405B2 (en) | 2001-12-22 | 2004-03-09 | Aventis Pharma Deutschland Gmbh | Substituted 4-phenyltetrahydroisoquinolinium salts, process for their preparation, their use as a medicament, and medicament containing them |
| DE10163992A1 (de) | 2001-12-24 | 2003-07-03 | Merck Patent Gmbh | 4-Aryl-chinazoline |
| US7119120B2 (en) | 2001-12-26 | 2006-10-10 | Genzyme Corporation | Phosphate transport inhibitors |
| PL223471B1 (pl) | 2002-03-15 | 2016-10-31 | Cypress Bioscience Inc | Kompozycja farmaceutyczna zawierająca milnacypran do stosowania w leczeniu zespołu nadwrażliwości jelita grubego |
| ATE337326T1 (de) | 2002-03-19 | 2006-09-15 | Genzyme Corp | Hemmer des phosphattransports |
| JP2005531557A (ja) | 2002-05-17 | 2005-10-20 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフトング | 選択的オピエート受容体モジュレーターとして効果的な化合物の使用 |
| US7014862B2 (en) | 2002-05-20 | 2006-03-21 | The Procter & Gamble Company | Chewable compositions containing a gel-forming extract of psyllium |
| US6923466B2 (en) | 2002-12-17 | 2005-08-02 | James Tsai | Collapsible handcart capable of extending the area of carrier by operating handle |
| US7304036B2 (en) | 2003-01-28 | 2007-12-04 | Microbia, Inc. | Methods and compositions for the treatment of gastrointestinal disorders |
| US20050054705A1 (en) | 2003-02-04 | 2005-03-10 | Aventis Pharma Deutschland Gmbh | N-substituted (benzoimidazol-2-yl) phenylamines, process for their preparation, their use as medicament or diagnostic aid, and medicament comprising them |
| US7026303B2 (en) | 2003-02-18 | 2006-04-11 | The Procter & Gamble Company | Compositions comprising a polysaccharide component and one or more coating layers |
| WO2004085448A2 (en) | 2003-03-19 | 2004-10-07 | Genzyme Corporation | Unsaturated phosphinyl-phosphonate phosphate transport inhibitors |
| DE10312963A1 (de) | 2003-03-24 | 2004-10-07 | Aventis Pharma Deutschland Gmbh | Substituierte 4-Phenyltetrahydroisochinoline, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament, sowie sie enthaltendes Medikament |
| US7241775B2 (en) | 2003-03-24 | 2007-07-10 | Sanofi-Aventis Deutschland Gmbh | Composition, process of making, and medical use of substituted 4-phenyltetrahydroisoquinolines |
| US8134015B2 (en) | 2003-03-27 | 2012-03-13 | Kyowa Hakko Kirin Co., Ltd. | Compound inhibiting in vivo phosphorous transport and medicine containing the same |
| US20050244367A1 (en) | 2004-05-03 | 2005-11-03 | Ilypsa, Inc. | Phospholipase inhibitors localized in the gastrointestinal lumen |
| MXPA06013236A (es) | 2004-05-14 | 2007-02-28 | Univ North Carolina | Prouroguanilina, y analogos sinteticos o productos de escision proteolitica derivados de la misma, como agentes terapeuticos y de diagnostico para enfermedades que comprenden hemeostasis de sales y/o fluidos. |
| DE102004046492A1 (de) | 2004-09-23 | 2006-03-30 | Sanofi-Aventis Deutschland Gmbh | Substituierte 4-Phenyltetrahydroisochinoline, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament, sowie sie enthaltendes Medikament |
| DE102004054847A1 (de) | 2004-11-13 | 2006-05-24 | Sanofi-Aventis Deutschland Gmbh | Substituierte Benzoylguanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament |
| DE102005001411A1 (de) | 2005-01-12 | 2006-07-27 | Sanofi-Aventis Deutschland Gmbh | Substituierte 4-Phenyltetrahydroisochinoline, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament, sowie sie enthaltendes Medikament |
| DE102005044815A1 (de) | 2005-09-20 | 2007-03-22 | Sanofi-Aventis Deutschland Gmbh | Verwendung von Inhibitoren des Na+/H+ Austauschers, Subtyp 5 (NHE5) zur Gedächtnisverbesserung |
| DE102005044817A1 (de) | 2005-09-20 | 2007-03-22 | Sanofi-Aventis Deutschland Gmbh | Substituierte 4-Phenyltetrahydroisochinoline, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament, sowie sie enthaltendes Medikament |
| AU2006311765A1 (en) | 2005-11-03 | 2007-05-18 | Ilypsa, Inc. | Phospholipase inhibitors, including multi-valent phospholipase inhibitors, and use thereof, including as lumen-localized phospholipase inhibitors |
| US7666898B2 (en) | 2005-11-03 | 2010-02-23 | Ilypsa, Inc. | Multivalent indole compounds and use thereof as phospholipase-A2 inhibitors |
| WO2008002971A2 (en) | 2006-06-29 | 2008-01-03 | Microbia, Inc. | Methods and compositions for the treatment of gastrointestinal disorders |
| EP2129683A4 (en) | 2007-02-26 | 2011-01-05 | Ironwood Pharmaceuticals Inc | METHODS AND COMPOSITIONS FOR TREATMENT OF HEART FAILURE AND OTHER DISORDERS |
| WO2008137318A1 (en) | 2007-05-04 | 2008-11-13 | Ironwood Pharmaceuticals, Inc. | Compositions and methods for treating disorders associated with salt or fluid retention |
| CA2735842A1 (en) | 2008-09-02 | 2010-03-11 | Sanofi-Aventis | Substituted aminoindanes and analogs thereof, and the pharmaceutical use thereof |
| US10543207B2 (en) | 2008-12-31 | 2020-01-28 | Ardelyx, Inc. | Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders |
| JP5502106B2 (ja) * | 2008-12-31 | 2014-05-28 | アーデリクス，インコーポレーテッド | 体液貯留または塩分過負荷と関連する障害および消化管障害の治療におけるｎｈｅ媒介性アンチポートを阻害するための組成物および方法 |
| EP2590656B1 (en) | 2010-07-07 | 2017-11-15 | Ardelyx, Inc. | Compounds and methods for inhibiting phosphate transport |
| JP5827328B2 (ja) | 2010-07-07 | 2015-12-02 | アーデリクス，インコーポレーテッド | リン酸輸送を阻害する化合物及び方法 |
| WO2012006475A1 (en) | 2010-07-07 | 2012-01-12 | Ardelyx, Inc. | Compounds and methods for inhibiting phosphate transport |
| EP2590655B1 (en) | 2010-07-07 | 2015-06-24 | Ardelyx, Inc. | Compounds and methods for inhibiting phosphate transport |
| IN2014DN01883A (enExample) * | 2011-09-14 | 2015-05-15 | Proximagen Ltd | |
| WO2014029984A1 (en) * | 2012-08-21 | 2014-02-27 | Ardelyx, Inc. | Compounds and methods for inhibiting nhe-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders |
| KR102138390B1 (ko) | 2012-08-21 | 2020-07-27 | 알데릭스, 인코포레이티드 | 체액 저류 또는 염 과부하와 연관된 장애 및 위장관 장애의 치료에서 ｎｈｅ-매개된 역수송 저해를 위한 화합물 및 방법 |
| KR102287207B1 (ko) | 2013-04-12 | 2021-08-09 | 알데릭스, 인코포레이티드 | Nhe3-결합 화합물 및 포스페이트 수송을 저해하는 방법 |
| BR112017000691B1 (pt) * | 2014-07-25 | 2023-02-14 | Taisho Pharmaceutical Co., Ltd | Feniltetra-hidroisoquinolina substituído com heteroari-la, seu uso, medicamento, inibidores de nhe3, de absorção de sódio e de absorção de fósforo, promotor de secre-ção de água intestinal e fármaco profilático ou terapêu-tico para constipação |
| UA126283C2 (uk) * | 2017-01-09 | 2022-09-14 | Арделікс, Інк. | Сполуки, придатні для лікування розладів шлунково-кишкового тракту |
-
2018
- 2018-01-09 CA CA3049679A patent/CA3049679A1/en not_active Abandoned
- 2018-01-09 MX MX2019008171A patent/MX2019008171A/es unknown
- 2018-01-09 WO PCT/US2018/013027 patent/WO2018129557A1/en not_active Ceased
- 2018-01-09 EA EA201991676A patent/EA201991676A1/ru unknown
- 2018-01-09 CN CN201880011759.6A patent/CN110291082A/zh active Pending
- 2018-01-09 MA MA047203A patent/MA47203A/fr unknown
- 2018-01-09 BR BR112019013963A patent/BR112019013963A2/pt not_active Application Discontinuation
- 2018-01-09 JP JP2019537134A patent/JP2020505333A/ja active Pending
- 2018-01-09 AU AU2018206479A patent/AU2018206479B2/en active Active
- 2018-01-09 EP EP18701988.0A patent/EP3565811A1/en not_active Withdrawn
- 2018-01-09 US US16/476,835 patent/US11147884B2/en active Active
- 2018-01-09 KR KR1020197023351A patent/KR20190128626A/ko not_active Ceased
-
2019
- 2019-07-03 IL IL267821A patent/IL267821B2/en unknown
- 2019-07-08 ZA ZA2019/04460A patent/ZA201904460B/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020505333A5 (enExample) | ||
| IL267821B2 (en) | nhe-mediated antiport inhibitors | |
| JP7065115B2 (ja) | フェロポーチン阻害剤塩 | |
| RU2469032C2 (ru) | Производные 2-(пиперидин-4-ил)-4-фенокси- или фениламинопиримидина в качестве ненуклеозидных ингибиторов обратной транскриптазы | |
| JP4723242B2 (ja) | 炎症および免疫障害治療用ｃｃｒ１アンタゴニストとして使用するための１−アリール−４−置換ピペラジン誘導体 | |
| ES2618812T3 (es) | Antagonistas del receptor mineralocorticoide | |
| RU2015143191A (ru) | Дигидропирролопиридиновые ингибиторы бромодоменов | |
| JP2013510876A5 (enExample) | ||
| JP2008518999A5 (enExample) | ||
| JP2009544602A5 (enExample) | ||
| JP2010513272A5 (enExample) | ||
| JP2017522346A5 (enExample) | ||
| AU2005270132A1 (en) | Anti-inflammatory medicaments | |
| RU2008116313A (ru) | Диарилминсодержащие соединения, композиции и их примеение в качестве модуляторов рецепторов с-кit | |
| EP1836173A4 (en) | ANTI-INFLAMMATORY DRUGS | |
| RU2011149360A (ru) | Замещенные фенилмочевины и фениламиды в качестве лигандов ваниллоидных рецепторов | |
| JP2019519586A5 (enExample) | ||
| JP2008513464A5 (enExample) | ||
| CA2628844A1 (en) | Pyrazole derivatives and their medical use | |
| JP2010510297A (ja) | 置換２，５−ジヒドロ−３ｈ−ピラゾロ［４，３−ｃ］ピリダジン−３−オン誘導体、該誘導体の調製およびカンナビノイドｃｂ１受容体リガンドとしての同誘導体の使用 | |
| JP2014531436A5 (enExample) | ||
| RU2017130474A (ru) | Замещенные триаозлы и способы, касающиеся их | |
| WO2018114783A1 (en) | Tetrazole containing compounds | |
| US20150291563A1 (en) | 4,5-dihydro-1h-pyrazole derivative or salts thereof, and pharmaceutical composition comprising same | |
| AU2006237365A1 (en) | 2,3 substituted pyrazine sulfonamides as inhibitors of CRTH2 |